Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) - Schachter, J; Ribas, A; Long, G V (Lancet (London, England), 2017)
et al.